EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV

Filippo Pietrantonio, Francesca Bergamo, Daniele Rossini, Filippo Ghelardi, Maria Caterina De Grandis, Marco Maria Germani, Giulia Barsotti, Vincenzo Formica, Giovanni Luca Frassineti, Giorgia Boscolo, Saverio Cinieri, Samantha Di Donato und 8 weitere

European Journal of Cancer · 2023-12 · 195 · 113396

DOI: 10.1016/j.ejca.2023.113396 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2023-12. Verfasst von Filippo Pietrantonio und 19 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori,, Milano, Italy. Hauptthemen laut MEDLINE: Colonic Neoplasms, Colorectal Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colonic NeoplasmsColorectal NeoplasmsRectal NeoplasmsAgedHumansAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsErbB ReceptorsFluorouracilPanitumumabProtein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins B-raf

Stichwörter der Autor:innen

anti-EGFR resistancecomprehensive genomic profilingelderly patientsmCRCprognostic biomarkers

Substanzen

Antibodies, MonoclonalBRAF protein, humanErbB ReceptorsFluorouracilPanitumumabProtein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins B-raf

Autor:innen und Institutionen

  • Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori,, Milano, Italy.
  • Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.
  • Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy; Unit of Medical Oncology 2, University Hospital of Pisa, Pisa, Italy.
  • Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
  • Medical Oncology Unit, Policlinico Tor Vergata, Roma, Italy.
  • Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), Meldola, Italy.

Förderung

  • Ministero della Salute

Zitieren

APA

Pietrantonio, F., Bergamo, F., Rossini, D., Ghelardi, F., De Grandis, M. C., Germani, M. M., Barsotti, G., Formica, V., Frassineti, G. L., Boscolo, G., Cinieri, S., Di Donato, S., Antonuzzo, L., Antoniotti, C., Ambrosini, M., Piva, V. M., Nichetti, F., Fassan, M., Cremolini, C., & Lonardi, S. (2023). Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV. European Journal of Cancer, 195, 113396. https://doi.org/10.1016/j.ejca.2023.113396

Vancouver

Pietrantonio F, Bergamo F, Rossini D, Ghelardi F, De Grandis MC, Germani MM, et al. Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV. European Journal of Cancer. 2023;195:113396. doi:10.1016/j.ejca.2023.113396

BibTeX
@article{Pietrantonio2023,
  author = {Pietrantonio, Filippo and Bergamo, Francesca and Rossini, Daniele and Ghelardi, Filippo and De Grandis, Maria Caterina and Germani, Marco Maria and Barsotti, Giulia and Formica, Vincenzo and Frassineti, Giovanni Luca and Boscolo, Giorgia and Cinieri, Saverio and Di Donato, Samantha and Antonuzzo, Lorenzo and Antoniotti, Carlotta and Ambrosini, Margherita and Piva, Vittoria Matilde and Nichetti, Federico and Fassan, Matteo and Cremolini, Chiara and Lonardi, Sara},
  title = {Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV},
  journal = {European Journal of Cancer},
  year = {2023},
  volume = {195},
  pages = {113396},
  doi = {10.1016/j.ejca.2023.113396}
}
Kostenlos starten →